X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients, by leveraging Caris' proprietary ADAPT Biotargeting platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $1,400.0 million Upfront Cash: Undisclosed
Deal Type: Partnership April 04, 2024
Details:
Under the agreement, Moderna will leverage Caris' library of de-identified, multi-modal data solutions to enhance Moderna's oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of resistance mechanisms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 24, 2023
Details:
The collaboration focuses to accelerate precision medicine approaches across five of Flare's programs, including its lead precision oncology program, FX-909, a small molecule inhibitor targeting PPARG, into clinical trials through advanced molecular profiling approaches.
Lead Product(s): 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area: Oncology Product Name: FX-909
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Flare Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 13, 2023
Details:
Under the partnership, Incyte will leverage Caris’ data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 07, 2023
Details:
Under the terms of the new agreement, Xencor will receive exclusive worldwide rights to research, develop and commercialize antibody products directed to up to three targets discovered under the collaboration.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Xencor
Deal Size: $187.0 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 05, 2023
Details:
Caris’ proprietary ADAPT biotargeting system is able to identify many cancer-specific proteins that would elude classical identification methods, increasing the potential to identify truly novel targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Under the terms of the agreement, Caris will help BriaCell with efficient patient identification, accelerating enrollment for its current Phase I/II clinical trial of Bria-IMT in advanced metastatic breast cancer of certain genetically defined subgroups.
Lead Product(s): SV-BR-1-GM,Retifanlimab
Therapeutic Area: Oncology Product Name: Bria-IMT
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: BriaCell Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 14, 2022
Details:
Through this partnership, Caris will sequence individuals’ complete exome and transcriptome, leverage real-world data to help inform clinical development and help identify eligible patients for Zentalis’ clinical trials.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Zentalis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 29, 2022
Details:
Molecular Intelligence Trials (MI Trials) collaboration will enhance identification of patients with NTRK fusion-positive solid tumors, including primary and metastatic CNS tumors potentially eligible for enrollment in the ongoing PBI-200-101 Phase 1/2 clinical study.
Lead Product(s): PBI-200
Therapeutic Area: Oncology Product Name: PBI-200
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Pyramid Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 10, 2022
Details:
The partnership will focus on two therapeutic programs, the first of which is HotSpot's novel allosteric inhibitor of the E3 ubiquitin ligase CBL-B, a target in cancer immunotherapy, spanning from pre-First in Human trials through potential Companion Diagnostics and launch.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: HotSpot Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
